Increased β‐endorphin and autotaxin in patients with prurigo
Abstract Objectives Prurigo is a treatment‐resistant inflammatory disease of unknown etiology. Persistent and severe itch is a major and important clinical symptom, but pathological mechanisms and/or actual mediators for itch in prurigo remain to be defined. Methods We investigated blood levels of β...
Main Authors: | Takahiro Ishikawa, Takashi Hashimoto, Takichi Munetsugu, Hiroo Yokozeki, Takahiro Satoh |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-08-01
|
Series: | Journal of Cutaneous Immunology and Allergy |
Subjects: | |
Online Access: | https://doi.org/10.1002/cia2.12062 |
Similar Items
-
Out‐of‐pocket expenditures in adult patients with prurigo nodularis in France
by: Laurent Misery, et al.
Published: (2023-06-01) -
Dupilumab as promising treatment for prurigo nodularis: current evidences
by: Ludovica Toffoli, et al.
Published: (2022-04-01) -
Characterization of Paediatric Prurigo Nodularis: A Multicentre Retrospective, Observational Study
by: Rotem Kyvayko, et al.
Published: (2024-02-01) -
Spontaneous resolution of intractable prurigo nodularis after subinsular cortex stroke
by: Sakeen W. Kashem, MD, PhD, et al.
Published: (2023-02-01) -
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks
by: Claudia Paganini, et al.
Published: (2024-02-01)